Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks
Sionna Therapeutics topline clinical data for cystic fibrosis programs disappoints, opting to discontinue its SION-719 candidate.
Sionna stopped working on a medicine it was testing because the early results weren't good enough. When a company has to give up on a drug they've invested in, it's a sign that project won't make them money.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.